S103: TRIAL IN PROGRESS: A PHASE 2, OPEN‐LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF THE PKR ACTIVATOR ETAVOPIVAT (FT‐4202) IN PATIENTS WITH THALASSEMIA OR SICKLE CELL DISEASE.

Autor:	Lal, A., Brown, C., Coates, T., Kalfa, T., Kwiatkowski, J.L., Brevard, J., Trenor, C., Wood, K., Sheth, S.
Zdroj:	HemaSphere; Jan2022 Supplement 1, Vol. 6, p2-2, 1p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text